FGF-19 CRISPR/Cas9 KO Plasmid (h): sc-401725
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FGF-19 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FGF-19 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FGF-19 Antibody (H-12): sc-390621
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FGF-19 CRISPR/Cas9 KO Plasmid (h) | sc-401725 | 20 µg | $397.00 |
Overview
FGF19 encodes fibroblast growth factor 19 (FGF-19), an endocrine FGF that signals primarily through FGFR4 in conjunction with the co-receptor β-Klotho to regulate metabolic homeostasis. In hepatocytes and enterocytes, FGF-19 participates in bile acid feedback control by suppressing CYP7A1 and integrating with FXR-driven transcriptional programs that influence lipid and glucose metabolism. Downstream signaling engages MAPK/ERK and related kinase cascades, linking FGF-19 to cell growth, differentiation, and tissue-specific metabolic adaptation. Dysregulated FGF19 expression or signaling has been associated with altered bile acid metabolism and metabolic disease phenotypes, and it is frequently studied in the context of aberrant growth signaling in cancer biology.
FGF-19 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FGF19 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FGF19 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FGF19 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FGF-19 protein expression.
This CRISPR knockout system enables efficient generation of FGF19-deficient cell models for investigation of FGF-19 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FGF19 exon(s) critical for FGF-19 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FGF19 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FGF-19 CRISPR/Cas9 KO Plasmid (h) and FGF-19 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FGF19 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FGF-19 HDR Plasmid (h) and FGF-19 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FGF19 homology arms to support homology-directed repair at defined FGF19 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.